Europe Infectious Disease Diagnostics Market - Country-Wise Analysis

Focus on Product, Testing Location, Infectious Disease Type, Infection Type, Technology, and End User - Analysis and Forecast, 2021-2031

Published Year: 2022
SKU: BHP1188SA

8100

Share With All Colleagues Globally.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Markets

1.1    Product Definition
         1.1.1    Definitions
         1.1.2    Inclusion and Exclusion
1.2    Market Overview
1.3    Significant Technologies in Infectious Disease Diagnostics
1.4    Classification of Infectious Disease Diagnostics
1.5    Europe Footprint
1.6    Market Dynamics
         1.6.1    Impact Analysis
         1.6.2    Market Drivers
                     1.6.2.1    Increasing Prevalence of Infectious Diseases
                     1.6.2.2    Technological Innovation Resulting in Market Pull
                     1.6.2.3    Significant External Funding Supporting Market Growth
         1.6.3    Market Restraints
                     1.6.3.1    Uncertain Reimbursement Scenario
                     1.6.3.2    Lack of High Complexity Testing Centers
                     1.6.3.3    Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
         1.6.4    Market Opportunities
                     1.6.4.1    Massive Scope for Adoption of Infectious Disease Diagnostics in Emerging Nations
                     1.6.4.2    Technological Advancements in Molecular Techniques and Infectious Diagnostic Tests
1.7    COVID-19 Impact on Europe Infectious Disease Diagnostics Market
         1.7.1    COVID-19 Impact on Infectious Disease Diagnostics Market Size
         1.7.2    Realistic Growth Scenario
         1.7.3    Optimistic Growth Scenario
         1.7.4    Disruption in Europe Infectious Disease Diagnostics Market Due to COVID-19
1.8    Competitive Landscape
         1.8.1    Acquisitions
         1.8.2    Synergistic Activities
         1.8.3    Product Launches and Approvals
         1.8.4    Business Expansion Activities
         1.8.5    Market-Share Analysis (by Company)
         1.8.6    Growth-Share Analysis (by Technology)
1.9    Industry Insights
         1.9.1    Legal Requirements and Framework in Europe

2 Products

2.1    Overview
         2.1.1    System
         2.1.2    Kits and Reagents
         2.1.3    Software

3 Testing Location

3.1    Overview
         3.1.1    Laboratory Testing
         3.1.2    Point-of-Care Testing

4 Technology

4.1    Overview
         4.1.1    Polymerase Chain Reaction (PCR)
                     4.1.1.1    Real-Time PCR (RT-PCR)
                     4.1.1.2    Digital PCR (d-PCR)
         4.1.2    Next-Generation Sequencing
         4.1.3    Isothermal Nucleic Acid Amplification Technology (INAAT)
         4.1.4    Microarray
         4.1.5    In-Situ Hybridization (ISH)
         4.1.6    Immunodiagnostics
         4.1.7    Other Technologies

5 Infectious Disease Type

5.1    Overview
         5.1.1    Bacterial Infectious Diseases
         5.1.2    Viral Infectious Diseases
         5.1.3    Fungal Infectious Diseases
         5.1.4    Other Infectious Diseases

6 Infection Type

6.1    Overview
         6.1.1    Respiratory Infections
                     6.1.1.1    COVID-19 Infection
                     6.1.1.2    Influenza A and B
                     6.1.1.3    Respiratory Syncytial Virus
                     6.1.1.4    Mycoplasma Infections
                     6.1.1.5    Pertussis Infections
                     6.1.1.6    Other Respiratory Infections
         6.1.2    Hospital-Acquired Infections (HAIs)
         6.1.3    Sexually Transmitted Infections (STIs)
                     6.1.3.1    Hepatitis B
                     6.1.3.2    HIV-AIDS
                     6.1.3.3    Human Papillomavirus (HPV)
                     6.1.3.4    Neisseria Gonorrhea
                     6.1.3.5    Other STIs
         6.1.4    Other Infections

7 End User

7.1    Overview
         7.1.1    Hospitals
                     7.1.1.1    Hospitals (by Respiratory Infections)
                                    7.1.1.1.1    Hospitals (Influenza A and B)
                                    7.1.1.1.2    Hospitals (COVID-19 Infection)
                                    7.1.1.1.3    Hospitals (Respiratory Syncytial Virus (RSV))
                                    7.1.1.1.4    Hospitals (Mycoplasma Infections)
                                    7.1.1.1.5    Hospitals (Pertussis Infections)
                                    7.1.1.1.6    Hospitals (Other Respiratory Infections)
                     7.1.1.2    Hospitals (by Sexually Transmitted Infections (STIs))
                                    7.1.1.2.1    Hospitals (Hepatitis B)
                                    7.1.1.2.2    Hospitals (HIV-AIDS)
                                    7.1.1.2.3    Hospitals (HPV)
                                    7.1.1.2.4    Hospitals (Neisseria Gonorrhea)
                                    7.1.1.2.5    Hospitals (Other STIs)
         7.1.2    Diagnostic Centers
                     7.1.2.1    Diagnostic Centers (by Respiratory Infections)
                                    7.1.2.1.1    Diagnostic Centers (Influenza A and B)
                                    7.1.2.1.2    Diagnostic Centers (COVID-19 Infection)
                                    7.1.2.1.3    Diagnostic Centers (Respiratory Syncytial Virus (RSV))
                                    7.1.2.1.4    Diagnostic Centers (Mycoplasma Infections)
                                    7.1.2.1.5    Diagnostic Centers (Pertussis Infections)
                                    7.1.2.1.6    Diagnostic Centers (Other Respiratory Infections)
                     7.1.2.2    Diagnostic Centers (by Sexually Transmitted Infections (STIs))
                                    7.1.2.2.1    Diagnostic Centers (Hepatitis B)
                                    7.1.2.2.2    Diagnostic Centers (HIV-AIDS)
                                    7.1.2.2.3    Diagnostic Centers (HPV)
                                    7.1.2.2.4    Diagnostic Centers (Neisseria Gonorrhea)
                                    7.1.2.2.5    Diagnostic Centers (Other STIs)
         7.1.3    Out-Patient Clinics/General Practitioners
                     7.1.3.1    Out-Patient Clinics/General Practitioners (by Respiratory Infections)
                                    7.1.3.1.1    Out-Patient Clinics/General Practitioners (Influenza A and B)
                                    7.1.3.1.2    Out-Patient Clinics/General Practitioners (COVID-19 Infection)
                                    7.1.3.1.3    Out-Patient Clinics/General Practitioners (Respiratory Syncytial Virus (RSV))
                                    7.1.3.1.4    Out-Patient Clinics/General Practitioners (Mycoplasma Infections)
                                    7.1.3.1.5    Out-Patient Clinics/General Practitioners (Pertussis Infections)
                                    7.1.3.1.6    Out-Patient Clinics/General Practitioners (Other Respiratory Infections)
                     7.1.3.2    Out-Patient Clinics/General Practitioners (by Sexually Transmitted Infections (STIs))
                                    7.1.3.2.1    Out-Patient Clinics/General Practitioners (Hepatitis B)
                                    7.1.3.2.2    Out-Patient Clinics/General Practitioners (HIV-AIDS)
                                    7.1.3.2.3    Out-Patient Clinics/General Practitioners (HPV)
                                    7.1.3.2.4    Out-Patient Clinics/General Practitioners (Neisseria Gonorrhea)
                                    7.1.3.2.5    Out-Patient Clinics/General Practitioners (Other STIs)
         7.1.4    Research Laboratories
                     7.1.4.1    Research Laboratories (by Respiratory Infections)
                                    7.1.4.1.1    Research Laboratories (Influenza A and B)
                                    7.1.4.1.2    Research Laboratories (COVID-19 Infection)
                                    7.1.4.1.3    Research Laboratories (Respiratory Syncytial Virus (RSV))
                                    7.1.4.1.4    Research Laboratories (Mycoplasma Infections)
                                    7.1.4.1.5    Research Laboratories (Pertussis Infections)
                                    7.1.4.1.6    Research Laboratories (Other Respiratory Infections)
                     7.1.4.2    Research Laboratories (by Sexually Transmitted Infections (STIs))
                                    7.1.4.2.1    Research Laboratories (Hepatitis B)
                                    7.1.4.2.2    Research Laboratories (HIV-AIDS)
                                    7.1.4.2.3    Research Laboratories (HPV)
                                    7.1.4.2.4    Research Laboratories (Neisseria Gonorrhea)
                                    7.1.4.2.5    Research Laboratories (Other STIs)
         7.1.5    Other End Users

8 Regions

8.1    Overview
8.2    Europe-5
         8.2.1    Europe Infectious Disease Diagnostics Market (by Infectious Disease Type)
         8.2.2    Germany
         8.2.3    U.K.
         8.2.4    France
         8.2.5    Italy
         8.2.6    Spain
8.3    Baltic
         8.3.1    Estonia
         8.3.2    Lithuania
         8.3.3    Latvia
8.4    Nordic
         8.4.1    Denmark
         8.4.2    Sweden
         8.4.3    Norway
         8.4.4    Finland
8.5    Rest-of- Europe

9 Company Profiles

9.1    Overview
9.2    Abbott
         9.2.1    Company Overview
         9.2.2    Role of Abbott in the Europe Infectious Disease Diagnostics Market    
         9.2.3    Key Competitors of the Company
         9.2.4    Key Customers of the Company
         9.2.5    Corporate Strategies
         9.2.6    Business Strategies
         9.2.7    Financials
         9.2.8    Key Insights about the Financial Health of the Company
         9.2.9    SWOT Analysis
9.3    Agilent Technologies, Inc.
         9.3.1    Company Overview
         9.3.2    Role of Agilent Technologies, Inc. in the Europe Infectious Disease Diagnostics Market
         9.3.3    Key Competitors of the Company
         9.3.4    Key Customers of the Company
         9.3.5    Corporate Strategies
         9.3.6    Business Strategies
         9.3.7    Financials
         9.3.8    Key Insights about the Financial of the Company
         9.3.9    SWOT Analysis
9.4    Becton, Dickinson and Company (BD)
         9.4.1    Company Overview
         9.4.2    Role of Becton, Dickinson and Company (BD) in the Europe Infectious Disease Diagnostics Market
         9.4.3    Key Competitors of the Company
         9.4.4    Key Customers of the Company
         9.4.5    Corporate Strategies
         9.4.6    Business Strategies
         9.4.7    Financials
         9.4.8    Key Insights about the Financial Health of the Company
         9.4.9    SWOT Analysis
9.5    bioMérieux SA
         9.5.1    Company Overview
         9.5.2    Role of bioMérieux SA in the Europe Infectious Disease Diagnostics Market
         9.5.3    Key Competitors of the Company
         9.5.4    Key Customers of the Company
         9.5.5    Business Strategies
         9.5.6    Financials
         9.5.7    Key Insights about the Financial Health of the Company
         9.5.8    SWOT Analysis
9.6    Bio-Rad Laboratories, Inc.
         9.6.1    Company Overview
         9.6.2    Role of Bio-Rad Laboratories, Inc. in the Europe Infectious Disease Diagnostics Market
         9.6.3    Key Competitors of the Company
         9.6.4    Key Customers of the Company
         9.6.5    Corporate Strategies
         9.6.6    Business Strategies
         9.6.7    Financials
         9.6.8    Key Insights about the Financial Health of the Company
         9.6.9    SWOT Analysis
9.7    Danaher
         9.7.1    Company Overview
         9.7.2    Role of Danaher in the Europe Infectious Disease Diagnostics Market
         9.7.3    Key Competitors of the Company
         9.7.4    Key Customers of the Company
         9.7.5    Corporate Strategies
         9.7.6    Business Strategies
         9.7.7    Financials
         9.7.8    Key Insights about the Financial Health of the Company
         9.7.9    SWOT Analysis
9.8    F. Hoffmann-La Roche Ltd
         9.8.1    Company Overview
         9.8.2    Role of F. Hoffmann-La Roche Ltd in the Europe Infectious Disease Diagnostics Market
         9.8.3    Key Competitors of the Company
         9.8.4    Key Customers of the Company
         9.8.5    Business Strategies
         9.8.6    Financials
         9.8.7    Key Insights about the Financial Health of the Company
         9.8.8    SWOT Analysis
9.9    Illumina, Inc.
         9.9.1    Company Overview
         9.9.2    Role of Illumina, Inc. in the Europe Infectious Disease Diagnostics Market
         9.9.3    Key Competitors of the Company
         9.9.4    Key Customers of the Company
         9.9.5    Financials
         9.9.6    Key Insights about the Financial Health of the Company
         9.9.7    SWOT Analysis
9.10    QIAGEN N.V.
           9.10.1    Company Overview
           9.10.2    Role of QIAGEN N.V. in the Europe Infectious Disease Diagnostics Market
           9.10.3    Key Competitors of the Company
           9.10.4    Key Customers of the Company
           9.10.5    Corporate Strategies
           9.10.6    Business Strategies
           9.10.7    Financials
           9.10.8    Key Insights about the Financial Health of the Company
           9.10.9    SWOT Analysis
9.11    Siemens Healthcare GmbH
           9.11.1    Company Overview
           9.11.2    Role of Siemens Healthcare GmbH in the Europe Infectious Disease Diagnostics Market
           9.11.3    Key Competitors of the Company
           9.11.4    Key Customers of the Company
           9.11.5    Business Strategies
           9.11.6    Financials
           9.11.7    Key Insights about the Financial Health of the Company
           9.11.8    SWOT Analysis
9.12    Thermo Fisher Scientific Inc.
           9.12.1    Company Overview
           9.12.2    Role of Thermo Fisher Scientific Inc. in the Europe Infectious Disease Diagnostics Market
           9.12.3    Key Competitors of the Company
           9.12.4    Key Customers of the Company
           9.12.5    Business Strategies
           9.12.6    Financials
           9.12.7    Key Insights about the Financial Health of the Company
           9.12.8    SWOT Analysis
9.13    PerkinElmer Inc.
           9.13.1    Company Overview
           9.13.2    Role of PerkinElmer Inc. in the Europe Infectious Disease Diagnostics Market
           9.13.3    Key Competitors of the Company
           9.13.4    Key Customers of the Company
           9.13.5    Financials
           9.13.6    Key Insights about the Financial Health of the Company
           9.13.7    SWOT Analysis
9.14    Hologic Inc. (Mobidiag Ltd.)
           9.14.1    Company Overview
           9.14.2    Role of Hologic Inc. (Mobidiag Ltd.) in the Europe Infectious Disease Diagnostics Market
           9.14.3    Key Competitors of the Company
           9.14.4    Key Customers of the Company
           9.14.5    Financials
           9.14.6    Key Insights about the Financial Health of the Company
           9.14.7    SWOT Analysis
Emerging Companies    
9.15    Abacus Diagnostica Oy
           9.15.1    Company Overview
           9.15.2    Role of Abacus Diagnostica Oy in the Europe Infectious Disease Diagnostics Market
           9.15.3    Key Competitors of the Company
           9.15.4    Key Customers of the Company
           9.15.5    Business Strategies
           9.15.6    SWOT Analysis
9.16    Novacyt Group.
           9.16.1    Company Overview
           9.16.2    Role of Novacyt Group. in the Europe Infectious Disease Diagnostics Market
           9.16.3    Key Competitors of the Company
           9.16.4    Key Customers of the Company
           9.16.5    Business Strategies
           9.16.6    Financials
           9.16.7    Key Insights about the Financial Health of the Company
           9.16.8    SWOT Analysis
9.17    Biocartis
           9.17.1    Company Overview
           9.17.2    Role of Biocartis in the Europe Infectious Disease Diagnostics Market
           9.17.3    Key Competitors of the Company
           9.17.4    Key Customers of the Company
           9.17.5    Business Strategies
           9.17.6    SWOT Analysis

List of Tables

Table 1:    COVID-19 Impact on Europe Infectious Disease Diagnostics Market
Table 2:    Products Launched by Various Manufacturers for Infectious Disease Diagnostics Research
Table 3:    Companies Providing System
Table 4:    Companies Providing Kits and Reagents
Table 5:    Companies Providing Software
Table 6:    PCR-Based Infectious Diagnostics Products
Table 7:    NGS-Based Infectious Diagnostics Products
Table 8:    Key Players Offering Infectious Diagnostics in the U.K.

List of Figures

Figure 1:    Distribution of Chronic Lower Respiratory Diseases
Figure 2:    Europe Infectious Disease Diagnostics Market (Realistic and Optimistic Scenario), $Million, 2020-2031
Figure 3:    Europe Infectious Disease Diagnostics Market Dynamics
Figure 4:    Share of Key Market Strategies and Developments, January 2018-March 2022
Figure 5:    Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 6:    Europe Infectious Disease Diagnostics Market (by Product), $Million, 2020 Vs. 2031
Figure 7:    Europe Infectious Disease Diagnostics Market (by Testing Location), $Million, 2020 Vs. 2031
Figure 8:    Europe Infectious Disease Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
Figure 9:    Europe Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020 Vs. 2031
Figure 10:    Europe Infectious Disease Diagnostics Market (by Infection Type), $Million, 2020 Vs. 2031
Figure 11:    Europe Infectious Disease Diagnostics Market (by End User), $Million, 2020 Vs. 2031
Figure 12:    Europe Infectious Disease Diagnostics Market: Research Methodology
Figure 13:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 14:    Top-Down Approach (Segment-Wise Analysis)
Figure 15:    Europe Infectious Disease Diagnostics Market Segmentation
Figure 16:    Role of Infectious Disease Diagnostics in Healthcare
Figure 17:    Classification of Europe Infectious Disease Diagnostics
Figure 18:    Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 19:    Europe Infectious Disease Diagnostics Market Dynamics
Figure 20:    Distribution of Chronic Lower Respiratory Diseases
Figure 21:    Impact of COVID-19 on Europe Infectious Disease Diagnostics Market
Figure 22:    Europe Infectious Disease Diagnostics Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
Figure 23:    Europe Infectious Disease Diagnostics Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
Figure 24:    COVID-19 Impact Analysis of Europe Infectious Disease Diagnostics Market, 2019-2025
Figure 25:    Share of Key Developments and Strategies, January 2018–March 2022
Figure 26:    Share of Acquisitions (by Company), January 2018-March 2022
Figure 27:    Share of Synergistic Activities (by Company), January 2018-March 2022
Figure 28:    Share of Product Launches and Approvals (by Company), January 2018-March 2022
Figure 29:    Share of Business Expansion Activities (by Company), January 2018-March 2022
Figure 30:    Market-Share Analysis for Europe Infectious Disease Diagnostics Market, $Million, 2019 and 2020
Figure 31:    Growth-Share Analysis of Europe Infectious Disease Diagnostics Market (by Technology), 2020-2031
Figure 32:    Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
Figure 33:    Share of Europe Infectious Disease Diagnostics Market (by Product), $Million, 2020 and 2031
Figure 34:    Europe Infectious Disease Diagnostics Market (System), $Million, 2020-2031
Figure 35:    General Workflow of a Molecular Diagnostic Kit
Figure 36:    Europe Infectious Disease Diagnostics Market (Kits and Reagents), $Million, 2020-2031
Figure 37:    Aspects of Software Development
Figure 38:    Europe Infectious Disease Diagnostics Market (Software), $Million, 2020-2031
Figure 39:    Europe Infectious Disease Diagnostics Market (by Testing Location)
Figure 40:    Share of Europe Infectious Disease Diagnostics Market (by Testing Location), $Million, 2020 and 2031
Figure 41:    Europe Infectious Disease Diagnostics Market (Laboratory Testing), $Million, 2020-2031
Figure 42:    Europe Infectious Disease Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
Figure 43:    Europe Infectious Disease Diagnostics Market (by Technology)
Figure 44:    Share of Europe Infectious Disease Diagnostics Market (by Technology), $Million, 2020 and 2031
Figure 45:    Europe Infectious Disease Diagnostics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
Figure 46:    Europe Infectious Disease Diagnostics Market (Real-Time PCR (RT-PCR), by Polymerase Chain Reaction (PCR)), $Million, 2020-2031
Figure 47:    Europe Infectious Disease Diagnostics Market (Digital PCR (d-PCR), by Polymerase Chain Reaction (PCR)), $Million, 2020-2031
Figure 48:    Europe Infectious Disease Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
Figure 49:    Europe Infectious Disease Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
Figure 50:    Europe Infectious Disease Diagnostics Market (Microarray), $Million, 2020-2031
Figure 51:    Europe Infectious Disease Diagnostics Market (In-Situ Hybridization (ISH)), $Million, 2020-2031
Figure 52:    Europe Infectious Disease Diagnostics Market (Immunodiagnostics), $Million, 2020-2031
Figure 53:    Europe Infectious Disease Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 54:    Europe Infectious Disease Diagnostics Market (by Infectious Disease Type)
Figure 55:    Europe Infectious Disease Diagnostics Market (by Infectious Diseases Type), $Million, 2020 and 2031
Figure 56:    Europe Infectious Disease Diagnostics Market (Bacterial Infectious Diseases), $Million, 2020-2031
Figure 57:    Europe Infectious Disease Diagnostics Market (Viral Infectious Diseases), $Million, 2020-2031
Figure 58:    Europe Infectious Disease Diagnostics Market (Fungal Infectious Diseases), $Million, 2020-2031
Figure 59:    Europe Infectious Disease Diagnostics Market (Other Infectious Diseases), $Million, 2020-2031
Figure 60:    Europe Infectious Disease Diagnostics Market (by Infection Type)
Figure 61:    Europe Infectious Disease Diagnostics Market (by Infection Type), $Million, 2020 and 2031
Figure 62:    Europe Infectious Disease Diagnostics Market (Respiratory Infections), $Million, 2020-2031
Figure 63:    Europe Infectious Disease Diagnostics Market (COVID-19 Infection, by Respiratory Infections), $Million, 2020-2031
Figure 64:    Europe Infectious Disease Diagnostics Market (Influenza A and B, by Respiratory Infections), $Million, 2020-2031
Figure 65:    Europe Infectious Disease Diagnostics Market (Respiratory Syncytial Virus, by Respiratory Infections), $Million, 2020-2031
Figure 66:    Europe Infectious Disease Diagnostics Market (Mycoplasma Infections, by Respiratory Infections), $Million, 2020-2031
Figure 67:    Europe Infectious Disease Diagnostics Market (Pertussis Infections, by Respiratory Infections), $Million, 2020-2031
Figure 68:    Europe Infectious Disease Diagnostics Market (Other Respiratory Infections, by Respiratory Infections), $Million, 2020-2031
Figure 69:    Europe Infectious Disease Diagnostics Market (Hospital-Acquired Infections (HAIs)), $Million, 2020-2031
Figure 70:    Europe Infectious Disease Diagnostics Market (Sexually Transmitted Infections), $Million, 2020-2031
Figure 71:    Europe Infectious Disease Diagnostics Market (Hepatitis B, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 72:    Europe Infectious Disease Diagnostics Market (HIV-AIDS, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 73:    Europe Infectious Disease Diagnostics Market (Human Papillomavirus (HPV), by Sexually Transmitted Infections), $Million, 2020-2031
Figure 74:    Europe Infectious Disease Diagnostics Market (Neisseria Gonorrhea, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 75:    Europe Infectious Disease Diagnostics Market (Other STIs, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 76:    Europe Infectious Disease Diagnostics Market (Other Infections), $Million, 2020-2031
Figure 77:    Europe Infectious Disease Diagnostics Market (by End User)
Figure 78:    Share of Europe Infectious Disease Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 79:    Europe Infectious Disease Diagnostics Market (Hospitals), $Million, 2020-2031
Figure 80:    Europe Infectious Disease Diagnostics Market (Hospitals, by Respiratory Infections), $Million, 2020-2031
Figure 81:    Europe Infectious Disease Diagnostics Market (Hospitals, Influenza A and B), $Million, 2020-2031
Figure 82:    Europe Infectious Disease Diagnostics Market (Hospitals, COVID-19 Infection), $Million, 2020-2031
Figure 83:    Europe Infectious Disease Diagnostics Market (Hospitals, Respiratory Syncytial Virus (RSV)), $Million, 2020-2031
Figure 84:    Europe Infectious Disease Diagnostics Market (Hospitals, Mycoplasma Infections), $Million, 2020-2031
Figure 85:    Europe Infectious Disease Diagnostics Market (Hospitals, Pertussis Infections), $Million, 2020-2031
Figure 86:    Europe Infectious Disease Diagnostics Market (Hospitals, Other Respiratory Infections), $Million, 2020-2031
Figure 87:    Europe Infectious Disease Diagnostics Market By (Hospitals, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 88:    Europe Infectious Disease Diagnostics Market (Hospitals, Hepatitis B), $Million, 2020-2031
Figure 89:    Europe Infectious Disease Diagnostics Market (Hospitals, HIV-AIDS), $Million, 2020-2031
Figure 90:    Europe Infectious Disease Diagnostics Market (Hospitals, HPV), $Million, 2020-2031
Figure 91:    Europe Infectious Disease Diagnostics Market (Hospitals, Neisseria Gonorrhea), $Million, 2020-2031
Figure 92:    Europe Infectious Disease Diagnostics Market (Hospitals, Other STIs), $Million, 2020-2031
Figure 93:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
Figure 94:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, by Respiratory Infections) $Million, 2020-2031
Figure 95:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Influenza A and B), $Million, 2020-2031
Figure 96:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, COVID-19 Infection), $Million, 2020-2031
Figure 97:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Respiratory Syncytial Virus), $Million, 2020-2031
Figure 98:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Mycoplasma Infections), $Million, 2020-2031
Figure 99:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Pertussis Infections), $Million, 2020-2031
Figure 100:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Other Respiratory Infections), $Million, 2020-2031
Figure 101:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 102:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Hepatitis B), $Million, 2020-2031
Figure 103:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, HIV-AIDS), $Million, 2020-2031
Figure 104:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, HPV), $Million, 2020-2031
Figure 105:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Neisseria Gonorrhea), $Million, 2020-2031
Figure 106:    Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Other STIs), $Million, 2020-2031
Figure 107:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
Figure 108:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, by Respiratory Infections), $Million, 2020-2031
Figure 109:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Influenza A and B), $Million, 2020-2031
Figure 110:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, COVID-19 Infection), $Million, 2020-2031
Figure 111:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus (RSV)), $Million, 2020-2031
Figure 112:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Mycoplasma Infections), $Million, 2020-2031
Figure 113:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Pertussis Infections), $Million, 2020-2031
Figure 114:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Other Respiratory Infections), $Million, 2020-2031
Figure 115:    Europe Infectious Disease Diagnostics Market By (Out-Patient Clinics/General Practitioners, by Sexually Transmitted Infections), $Million, 2020-2031
Figure 116:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Hepatitis B), $Million, 2020-2031
Figure 117:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, HIV-AIDS), $Million, 2020-2031
Figure 118:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, HPV), $Million, 2020-2031
Figure 119:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Neisseria Gonorrhea), $Million, 2020-2031
Figure 120:    Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Other STIs), $Million, 2020-2031
Figure 121:    Europe Infectious Disease Diagnostics Market (Research Laboratories), $Million, 2020-2031
Figure 122:    Europe Infectious Disease Diagnostics Market (Research Laboratories, by Respiratory Infections), Respiratory Infections, $Million, 2020-2031
Figure 123:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Influenza A and B), $Million, 2020-2031
Figure 124:    Europe Infectious Disease Diagnostics Market (Research Laboratories COVID-19 Infection), $Million, 2020-2031
Figure 125:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Respiratory Syncytial Virus (RSV)), $Million, 2020-2031
Figure 126:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Mycoplasma Infections), $Million, 2020-2031
Figure 127:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Pertussis Infections), $Million, 2020-2031
Figure 128:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Other Respiratory Infections), $Million, 2020-2031
Figure 129:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Sexually Transmitted Infections), $Million, 2020-2031
Figure 130:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Hepatitis B), $Million, 2020-2031
Figure 131:    Europe Infectious Disease Diagnostics Market (Research Laboratories, HIV-AIDS), $Million, 2020-2031
Figure 132:    Europe Infectious Disease Diagnostics Market (Research Laboratories, HPV), $Million, 2020-2031
Figure 133:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Neisseria Gonorrhea), $Million, 2020-2031
Figure 134:    Europe Infectious Disease Diagnostics Market (Research Laboratories, Other STIs), $Million, 2020-2031
Figure 135:    Europe Infectious Disease Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 136:    Europe Infectious Disease Diagnostics Market (by Region), $Million, 2020-2031
Figure 137:    Europe Infectious Disease Diagnostics Market (by Country), $Million, 2020 and 2031
Figure 138:    Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 139:    Europe: Market Dynamics
Figure 140:    Europe Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020 and 2031
Figure 141:    Germany Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 142:    Germany Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
Figure 143:    U.K. Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 144:    U.K. Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
Figure 145:    France Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 146:    France Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
Figure 147:    Italy Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 148:    Italy Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
Figure 149:    Spain Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 150:    Spain Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031
Figure 151:    Baltic Infectious Disease Diagnostics Market (by Country), $Million, 2020 and 2031
Figure 152:    Baltic Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 153:    Baltic: Market Dynamics
Figure 154:    Estonia Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 155:    Lithuania Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 156:    Latvia Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 157:    Nordic Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 158:    Denmark Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 159:    Sweden Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 160:    Norway Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 161:    Finland Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 162:    Rest-of-Europe Infectious Disease Diagnostics Market, $Million, 2020-2031
Figure 163:    Rest-of-Europe Infectious Disease Diagnostics Market, Thousand Unit, 2020-2031
Figure 164:    Share of Key Companies Profiled
Figure 165:    Abbott: Product Portfolio
Figure 166:    Abbott: Overall Financials, $Million, 2019-2021
Figure 167:    Abbott: Revenue (by Segment), $Million, 2019-2021
Figure 168:    Abbott: Revenue (by Region), $Million, 2019-2021
Figure 169:    Abbott: R&D Expenditure, $Million, 2019-2021
Figure 170:    Abbott: SWOT Analysis
Figure 171:    Agilent Technologies, Inc.: Product Portfolio
Figure 172:    Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 173:    Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 174:    Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 175:    Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 176:    Agilent Technologies, Inc.: SWOT Analysis
Figure 177:    Becton, Dickinson and Company (BD): Product Portfolio
Figure 178:    Becton, Dickinson and Company (BD): Overall Financials, $Million, 2019-2021
Figure 179:    Becton, Dickinson and Company (BD): Revenue (by Segment), $Million, 2019-2021
Figure 180:    Becton, Dickinson and Company (BD): Revenue (by Region), $Million, 2019-2021
Figure 181:    Becton, Dickinson and Company (BD): R&D Expenditure, $Million, 2019-2021
Figure 182:    Becton, Dickinson and Company: SWOT Analysis
Figure 183:    bioMérieux SA: Product Portfolio
Figure 184:    bioMérieux SA: Overall Financials, $Million, 2019-2021
Figure 185:    bioMérieux SA: Revenue (by Segment), $Million, 2019-2021
Figure 186:    bioMérieux SA: Revenue (by Region), $Million, 2019-2021
Figure 187:    bioMérieux SA: R&D Expenditure, $Million, 2019-2021
Figure 188:    bioMérieux SA: SWOT Analysis
Figure 189:    Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 190:    Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 191:    Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 192:    Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 193:    Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 194:    Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 195:    Danaher: Product Portfolio
Figure 196:    Danaher: Overall Financials, $Million, 2019-2021
Figure 197:    Danaher: Revenue (by Segment), $Million, 2019-2021
Figure 198:    Danaher: Revenue (by Region), $Million, 2019-2021
Figure 199:    Danaher: R&D Expenditure, $Million, 2019-2021
Figure 200:    Danaher: SWOT Analysis
Figure 201:    F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 202:    F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 203:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 204:    F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2018-2020
Figure 205:    F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 206:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 207:    Illumina, Inc.: Product Portfolio
Figure 208:    Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 209:    Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 210:    Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 211:    Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 212:    Illumina, Inc.: SWOT Analysis
Figure 213:    QIAGEN N.V.: Product Portfolio
Figure 214:    QIAGEN N.V.: Overall Financials, $Million, 2018-2020
Figure 215:    QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020
Figure 216:    QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020
Figure 217:    QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020
Figure 218:    QIAGEN N.V.: SWOT Analysis
Figure 219:    Siemens Healthcare GmbH: Product Portfolio
Figure 220:    Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021
Figure 221:    Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021
Figure 222:    Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021
Figure 223:    Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021
Figure 224:    Siemens Healthcare GmbH: SWOT Analysis
Figure 225:    Thermo Fisher Scientific Inc.: Product Portfolio
Figure 226:    Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 227:    Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 228:    Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 229:    Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 230:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 231:    PerkinElmer Inc.: Product Portfolio
Figure 232:    PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
Figure 233:    PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 234:    PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 235:    PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 236:    PerkinElmer, Inc.: SWOT Analysis
Figure 237:    Hologic Inc. (Mobidiag Ltd.): Product Portfolio
Figure 238:    Hologic Inc. (Mobidiag Ltd.): Overall Financials, $Million, 2019-2021
Figure 239:    Hologic Inc. (Mobidiag Ltd.): Revenue (by Segment), $Million, 2019-2021
Figure 240:    Hologic Inc. (Mobidiag Ltd.): Revenue (by Region), $Million, 2019-2021
Figure 241:    Hologic Inc. (Mobidiag Ltd.): R&D Expenditure, $Million, 2019-2021
Figure 242:    Hologic Inc. (Mobidiag Ltd.): SWOT Analysis
Figure 243:    Abacus Diagnostica Oy: Product Portfolio
Figure 244:    Abacus Diagnostica Oy: SWOT Analysis
Figure 245:    Novacyt Group.: Product Portfolio
Figure 246:    Novacyt Group.: Overall Financials, $Million, 2018-2020
Figure 247:    Novacyt Group.: Revenue (by Segment), $Million, 2018-2020
Figure 248:    Novacyt Group.: R&D Expenditure, $Million, 2018-2020
Figure 249:    Novacyt Group.: SWOT Analysis
Figure 250:    Biocartis: Product Portfolio
Figure 251:    Biocartis: SWOT Analysis

 
 

Market Report Coverage

Europe Infectious Disease Diagnostics Market

Base Year

2020

Market Size in 2021

$1,718.3 Million

Forecast Period

2021-2031

Value Projection and Estimation by 2031

$7,900.4 Million

CAGR During Forecast Period

16.48%

Number of Tables

8

Number of Pages

262

Number of Figures

251

Market Segmentation

•    Product (system, kits and reagents, and software)

•    Testing location (laboratory testing and point-of-care testing)

•    Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), immunodiagnostics, isothermal nucleic acid amplification technology (INAAT), microarray, in-situ hybridization (ISH), and other technologies)

•    Infectious Disease Type (bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, and other infectious diseases)

•    Infection Type (respiratory infections, hospital-acquired infections (HAI), sexually transmitted infections (STIs), and other infections)

•    End User (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)

Regional Segmentation

•    Europe-5 - Germany, U.K., France, Italy and Spain

•    Nordic- Denmark, Sweden, Norway and Finland

•    Baltic- Estonia, Lithuania and Latvia

•    Rest-of-Europe

Market Growth Drivers

•    Increasing Prevalence of Infectious Diseases

•    Technological Innovation Resulting in Market Pull

•    Significant External Funding Supporting Market Growth

Market Challenges

•    Uncertain Reimbursement Scenario

•    Lack of High Complexity Testing Centers

•    Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests

Market Opportunities

•    Massive Scope for Adoption of Infectious Disease Diagnostics in Emerging Nations

•    Technological Advancements in Molecular Techniques and Infectious Diagnostic Tests

Key Companies Profiled

Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., PerkinElmer Inc., Hologic Inc. (Mobidiag Ltd.), Abacus Diagnostica Oy, Novacyt Group, Biocartis

Key Questions Answered in this Report:

•    How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
        o    Product (system, kits and reagents, and software) 
        o    Testing location (laboratory testing and point-of-care testing)
        o    Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), immunodiagnostics, isothermal nucleic acid amplification technology (INAAT), microarray, in-situ hybridization (ISH), and other technologies)
        o    Infectious Disease Type (bacterial infectious diseases, viral infectious diseases, fungal infectious diseases, and other infectious diseases)
        o    Infection Type (respiratory infections, hospital-acquired infections (HAI), sexually transmitted infections (STIs), and other infections)
        o    End User (hospitals, diagnostic centers, out-patient clinics/general practitioners, research laboratories, and other end users)
        o    Region (EU-5, Baltic, Nordic, and Rest-of-Europe)
•    What are the major market drivers, challenges, and opportunities in the Europe infectious disease diagnostics market?
•    What are the underlying structures resulting in the emerging trends within the Europe infectious disease diagnostics market?
•    How is each segment of the Europe infectious disease diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
•    What are the key developmental strategies implemented by the major players to sustain in the competitive market?
•    What are the key regulatory implications in developed and developing regions for molecular diagnostics?
•    Who are the leading players with significant offerings to the Europe infectious disease diagnostics market? What is the current market dominance for each of these leading players?
•    What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which infectious disease product type is anticipated to have the most promising growth? 
•    What are the key applications in the Europe infectious disease diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
•    What are the major technologies that are employed in the Europe infectious disease diagnostics market? Which is the dominating technology?
•    Who are the primary end users of the Europe infectious disease diagnostics market? Which is the fastest-growing end-user segment in the Europe infectious disease diagnostics market?
•    Who are the key manufacturers in the Europe infectious disease diagnostics market, and what are their contributions? Also, what is the growth potential of each major infectious disease diagnostics manufacturer?
•    What is the scope of the Europe infectious disease diagnostics market in the EU’5, Baltic, and Nordic regions? Which infectious disease diagnostics product and end user dominate these regions?
•    What are the emerging trends in the Europe infectious disease diagnostics market? How are these trends revolutionizing the diagnostic procedure? 
•    Which technologies are anticipated to break through the current infectious diseases diagnostic regime?
•    Which companies are anticipated to be highly disruptive in the future and why?
•    What are the regulatory procedures required to unify the approval process for emerging infectious disease diagnostics? How will these enhance the reimbursement scenario?
•    What are the gaps in regularizing optimum infectious disease diagnostics adoption in regular healthcare routines? How are these gaps being tackled?

Report Summary

Market Overview

The use of infectious disease diagnostics kits, assays, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives. The increasing investments by healthcare companies to meet industry demand and the growing adoption of infectious disease diagnostics kits, tubes, and reagents among major end users are major factors propelling the growth of the Europe infectious disease diagnostics market. The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.

Europe Infectious Disease Diagnostics Market

Competitive Landscape

The Europe infectious disease diagnostics market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for infectious disease diagnostics from different product types. Key market players of the Europe infectious disease diagnostics market witnessed product launch and approval, business funding, and synergistic activities from January 2018 to March 2022. The inclination of companies toward product launches suggests that companies are constantly bringing new products to the market to test viral and bacterial infections, which is primarily attributed to an increase in demand for kits and assays by end users.

You may also like

Published Year: 2020

Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Ap

The global market for infectious disease rapid diagnostics is predicted to grow at a CAGR of...

 

Europe Infectious Disease Diagnostics Market - Country-Wise Analysis

Focus on Product, Testing Location, Infectious Disease Type, Infection Type, Technology, and End User - Analysis and Forecast, 2021-2031